← Leaderboards
John R Graybill
University Of Texas Hlth Sci Ctr San Ant
$322,851
Attributed
$322,851
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$322,851 · 3
By mechanism
N01$306,442 · 1
M01$16,409 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Hlth Sci Ctr San Ant
Same institution · by research overlap
- Thomas L. Patterson$31,498,176
- Steven Schenker$1,507,476
- Shou-Jiang Gao$2,009,230
- Rochelle N Shain$2,022,463
Others in their field
Top investigators on “Microorganism Disease Chemotherapy”
- Bruce D Walker · Massachusetts General Hospital$6,506,739
- Lawrence Corey · Fred Hutchinson Cancer Center$6,355,049
- Jane Ryan · Biota Scientific Management$5,628,310
- Christopher C. Whalen · Case Western Reserve University$5,165,940
- David B Clifford · Washington University$4,876,099
- William Robert Jacobs · Albert Einstein College Of Medicine$3,994,132
Research focus
Microorganism Disease ChemotherapyClinical Trial Phase ICandidiasisClinical ResearchDrug Screening /EvaluationHuman SubjectHuman Therapy EvaluationAntifungal AgentsFluconazoleEsophagus DisorderAdult Human (21+)Oral Pharyngeal DisorderAmphotericin BCandidaCryptococcosisCryptococcus NeoformansDisease /Disorder ModelDosageLaboratory MouseLongitudinal Human StudyNonhuman Therapy Evaluation
Grant awards (6)
MK 0991 VS FLUCONAZOLE IN ESOPHAGEAL CANDIDIASIS$0
M01 · FY2002 · RR
MK 0991 VS FLUCONAZOLE IN ESOPHAGEAL CANDIDIASIS$0
M01 · FY2002 · RR
MK 0991 VS FLUCONAZOLE IN ESOPHAGEAL CANDIDIASIS$0
M01 · FY2001 · RR
PRECLIN EVAL OF THERAPIES FOR TREATMENT OF CRYPTOCOCCOSI$306,442
N01 · FY2000 · AI
MK0991 VS. AMPHOTERICIN IN FLUCONAZOLE UNRESPONSIVE CANDIDIASIS$16,409
M01 · FY2000 · RR
MK 0991 VS FLUCONAZOLE IN ESOPHAGEAL CANDIDIASIS$0
M01 · FY2000 · RR